Nebivolol Krka (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractility. It also stimulates nitric‑oxide production in blood vessels, causing vasodilation and further lowering peripheral resistance and blood pressure.

The appropriate dose of nebivolol is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Nebivolol is a selective β1‑blocker with additional nitric‑oxide‑mediated vasodilatory effects, which may result in fewer metabolic side effects compared with non‑selective beta blockers. Its dual mechanism can offer better blood‑pressure control while preserving endothelial function.

Nebivolol Krka tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight and excessive heat to maintain product stability.

Nebivolol is taken orally, usually once daily with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water and do not crush or chew it unless instructed otherwise.

Serious risks include severe bradycardia, marked hypotension, and heart block. Patients should be monitored for signs of very slow heart rate, dizziness, fainting, or chest discomfort, and seek immediate medical attention if these occur.

Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, second‑ or third‑degree atrioventricular block, and those in cardiogenic shock. It should also be used with caution in individuals with severe liver or kidney impairment.